<DOC>
	<DOCNO>NCT00808119</DOCNO>
	<brief_summary>This first study conduct human RTI-336 , new chemical entity , evaluation focus safety , tolerability , pharmacokinetics RTI-336 follow administration single , oral dos . RTI-336 novel dopamine transporter inhibitor 3-phenyltropane class , currently develop RTI International potential pharmacotherapy treat cocaine dependence . Data study use plan define dose range subsequent study .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Single , Escalating Oral Doses RTI-336 Healthy , Male Subjects</brief_title>
	<detailed_description>Cocaine abuse epidemic United States since mid- late-1970s . It hypothesize medication treat cocaine addiction , , behavioral pharmacological property cocaine . Substantial evidence link euphoric high addictive property cocaine inhibition dopamine transporter ( DAT ) brain . Cocaine bind quickly potently transporter block presynaptic uptake dopamine , result subjective high reinforce effect preclinical study human . Compounds mimic DAT-binding property cocaine less stimulating act slow receptor onset offset may prove useful treatment cocaine dependence . The 3-phenyltropane analog , RTI-336 , potent selective DAT inhibitor demonstrate desirable pharmacological property preclinical specie appropriate compound test potential medication treat cocaine dependence . This first study conduct human RTI-336 , new chemical entity , evaluation focus safety , tolerability , pharmacokinetics RTI-336 follow administration single , oral dos , possibility identify maximum tolerate dose human . Data study use plan define dose range subsequent study .</detailed_description>
	<mesh_term>Cocaine-Related Disorders</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion meet : 1 . Subject provide sign dated , write informed consent prior studyspecific procedure perform , include washout medication compliance food/beverage restriction . 2 . Subject healthy adult male , 1850 year age , inclusive , time consent , body weight great equal 50 kg body mass index ( BMI ) range 1830 kg/m2 , BMI = weight ( kg ) / [ height ( ) ] 2 . 3 . Subject negative prestudy urine drug screen history cocaine use use illicit drug substance abuse within 12 month screen visit . Drugs substances analyze urine screen include cocaine , amphetamine , barbiturate , opioids , cannabinoids , benzodiazepine , phencyclidine , alcohol , cotinine . 4 . Subject nontobacco user prior user quit use tobacco least 90 day prior screen . 5 . Subject history cardiovascular disease normal ECG serum troponin screening . 6 . Subject negative hepatitis C antibody , hepatitis B surface antigen human immunodeficiency virus ( HIV ) screening . 7 . Subject good general health , opinion Investigator , determine medical history , physical examination , vital sign , 12lead ECG , clinical laboratory test screen . Additionally , subject 's clinical laboratory test result must meet following criterion : Within normal limit sodium , protein , total WBC , hematocrit , hemoglobin , reticulocyte count , platelet , AST ( SGOT ) , ALT ( SGPT ) , GGT , troponin I . Within upper limit normal 10 % low limit : BUN creatinine , bilirubin , total alkaline phosphatase , creatine kinase , LDH . Within 10 % normal range consider clinically significant : calcium chloride , phosphorus , albumin , globulin , cholesterol , triglyceride , RBC . No clinically significant abnormality : glucose , potassium , white blood cell differential , red blood cell index , uric acid , urinalysis . 8 . Subject willing use barrier contraception spermicide sexual intercourse enrol study least 30 day last dose study drug . 9 . Subject willing able comply study instruction restriction , available complete study assessment require protocol . 10 . Subjects fluent either English Spanish A subject exclude participation study follow criterion applies : 1 . Subject selfreports history chronic illicit drug use chronic use substance abuse . 2 . Subject positive urine drug/alcohol/cotinine test screen prior dose dose period . 3 . Subject history evidence hepatic , gastrointestinal , renal , respiratory , ophthalmic , cardiovascular , hematologic , endocrine/metabolic , neurologic , immunologic , oncologic psychiatric illness significant abnormality . 4 . Subject history and/or current major depression , psychotic symptom , anxiety disorder ( ) base Major Depressive Episode , Psychotic , Anxiety Disorder module Structured Clinical Interview DSM Disorders ( detail document study protocol ) . 5 . Subject family history psychiatric illness ( psychosis , depression , anxiety disorder ) . 6 . Subject abnormal ECG screen prior dose dose period . Premature atrial contraction premature ventricular contraction consider abnormal , bundle branch block , second third degree heart block , arrhythmia respiratory sinus arrhythmia . Abnormalities also include limited following : Heart Rate &lt; 45 &gt; 100 bpm ; PR interval &lt; 120 &gt; 220 msec ; QRS duration &lt; 70 &gt; 120 msec ; QTC interval ( Bazett ) &gt; 460 msec . 7 . Subject history family history QT prolongation , arrhythmia , uncontrolled hypertension . 8 . Subject history seizure , head injury , neurosurgery brain trauma , family history nontraumatic seizure . 9 . Subject positive hepatitis C antibodies screen , hepatitis B surface antigen HIV screening . 10 . Subject infection type clinically significant abnormality identify screen medical laboratory evaluation . 11 . Subject history use tobaccocontaining product within 90 day screen . 12 . Subject history significant alcohol consumption , define average weekly intake great 21 unit average daily intake great 3 unit , 1 unit equivalent halfpint ( 220 mL ) beer , 1 measure spirit , 1 glass ( 125 mL ) wine . 13 . Subject consume grapefruit grapefruitcontaining , poppyseed quininecontaining substance within 14 day first dose period . 14 . Subject used drug , include prescription nonprescription medication herbal supplement , within 30 day prior first dose study drug , exception acetaminophen , may take 24 hour prior dose dose period . 15 . Subject history presence gastrointestinal , hepatic renal disease , condition/surgical intervention know interfere absorption , distribution , metabolism , excretion drug . 16 . Subject acute gastrointestinal illness infection within 2 week prior first dose study drug . 17 . Subject participate investigational trial within 45 day prior first dose study drug . 18 . Subject unable donate blood , clot disorder ( ) , donated/lost &gt; 500 mL blood within 8 week prior screen . 19 . Subject unexplained weight loss gain &gt; 10 % within 30 day prior screen . 20 . Subject allergy 3phenyltropane analog ( e.g. , brasofensine , tesofensine ) , heparin , haloperidol , dopamine agonist , related compound . 21 . Subject unable respond recognize potential side effect study drug . This may include , limited , subject mental illness disorder . 22 . Subject condition set circumstance otherwise exclude judgment Investigator could interfere subject 's ability comply protocol requirement restriction completion study evaluation , could pose safety risk subject . 23 . Subject perform strenuous exercise within 48 hour prior screen examination refuse abstain strenuous exercise 48 hour prior 48 hour dose period , 48 hour prior day 8 visit , 48 hour prior followup visit . 24 . Subject screen serum troponin result clinical laboratory 's normal range .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2009</verification_date>
</DOC>